Dr Mitchell Lawrence is a Senior Research Fellow at Monash University with a part-time appointment at Peter Mac since 2017. His expertise includes the use of human preclinical models to study tumour biology, pathology, and novel therapies. In particular,
Dr Lawrence uses patient-derived xenografts (PDXs) and organoids from the Melbourne Urological Research Alliance (MURAL). These models represent the clinico-pathological and genomic spectrum of prostate cancer, from treatment-naïve primary tumors to castration-resistant metastases. For these multidisciplinary studies, Dr Lawrence works with a diverse team of collaborators, including urologists, oncologists, pathologists, bioinformaticians and patient advocates.
Dr Lawrence also collaborates with A/Prof Kaylene Simpson and the team from the Victorian Centre for Functional Genomics to develop high-throughput 3D assays with prostate cancer cells.
This manuscript reports 59 new patient-derived models of prostate cancer from the Melbourne Urological Research Alliance
This study used xenografts and organoids to demonstrate that combination therapy increases the effectiveness of PARP inhibitors for treating castration-resistant prostate cancer
This collaborative study with the Victorian Centre for Functional Genomics developed a new assay for analysing the responses of 3D organoids of prostate cancer cells to candidate therapies
This paper reports a new set of patient-derived models spanning the progression from castration sensitive localised prostate cancer to castration-resistant metastatic disease.
This article discussed the importance of ductal and intraductal pathologies of primary prostate cancer as markers of poor prognosis.